Olga V. Sakharova
Research Subjects
Olga V. Sakharova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Barry M. Brenner
1 shared publication- Fuad Alkhoury
Department of Surgery, Hospital of Saint Raphael, New Haven, Connecticut 06511, USA
1 shared publication - Jeremiah Thomas Martin
Department of Surgery, Division of Cardiothoracic Surgery, University of Kentucky, Lexington, Kentucky
1 shared publication - Maarten W. Taal
Professor of Medicine, Centre for Kidney Research and Innovation, School of Medicine, University of Nottingham, Nottingham, UK
1 shared publication - Paul Fiedler
Department of Surgery, Hospital of St. Raphael, 1450 Chapel Street, New Haven, CT 06511, USA
1 shared publication - Scott Helton
Department of Surgery, Hospital of St. Raphael, 1450 Chapel Street, New Haven, CT 06511, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Springer Nature in Cases Journal
- Vol. 2 (1) , 7965
Metastatic adenocarcinoma within a functioning adrenal adenoma: a case report
We present the case of a 54-year-old woman who underwent right adrenalectomy for palliation of Cushing's symptoms. She had recently been diagnosed with lung adenocarcinoma. Pathologic findings revealed a 5 cm adrenal adenoma with a metastatic adenocarcinoma deposit. The occurrence of tumor-to-tumor metastasis is rare, and the finding of a metastasis within a functional adrenal adenoma exceptionally so. Previously reported incidences of this finding in patients with lung cancer range from 0.14% to 0.63%. We review the literature regarding this unusual finding.
- 1 January 2009
- Published by Springer Nature in Cases Journal
- Vol. 2 (1) , 7965
Open AccessMetastatic adenocarcinoma within a functioning adrenal adenoma: a case report
We present the case of a 54-year-old woman who underwent right adrenalectomy for palliation of Cushing's symptoms. She had recently been diagnosed with lung adenocarcinoma. Pathologic findings revealed a 5 cm adrenal adenoma with a metastatic adenocarcinoma deposit. The occurrence of tumor-to-tumor metastasis is rare, and the finding of a metastasis within a functional adrenal adenoma exceptionally so. Previously reported incidences of this finding in patients with lung cancer range from 0.14% to 0.63%. We review the literature regarding this unusual finding.
- 1 November 2001
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 10 (6) , 727-738
Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factor
Although considerable improvement in the prognosis of diabetic nephropathy has been achieved in recent years due to intensive insulin and angiotensin-converting enzyme inhibitor treatment, these approaches do not provide complete protection against progression of diabetic nephropathy. An urgent need for additional novel therapies to prevent or further slow the progression of diabetic nephropathy motivated us to provide an up-to-date review with particular emphasis on the potential role of two growth factors--transforming growth factor-beta and connective tissue growth factor--in the pathogenesis of diabetic nephropathy. The most intensively studied to date, transforming growth factor-beta appears to play a central role in the pathogenesis of diabetic nephropathy. Recently, attention has focused on connective tissue growth factor, which mimics the biological activity of transforming growth factor-beta in profibrotic tissue formation. Thus, acting as a downstream mediator of the profibrotic activity of transforming growth factor-beta, connective tissue growth factor may constitute a more specific target for future antifibrotic therapies.
- 1 November 2001
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 10 (6) , 727-738
Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factor
Although considerable improvement in the prognosis of diabetic nephropathy has been achieved in recent years due to intensive insulin and angiotensin-converting enzyme inhibitor treatment, these approaches do not provide complete protection against progression of diabetic nephropathy. An urgent need for additional novel therapies to prevent or further slow the progression of diabetic nephropathy motivated us to provide an up-to-date review with particular emphasis on the potential role of two growth factors--transforming growth factor-beta and connective tissue growth factor--in the pathogenesis of diabetic nephropathy. The most intensively studied to date, transforming growth factor-beta appears to play a central role in the pathogenesis of diabetic nephropathy. Recently, attention has focused on connective tissue growth factor, which mimics the biological activity of transforming growth factor-beta in profibrotic tissue formation. Thus, acting as a downstream mediator of the profibrotic activity of transforming growth factor-beta, connective tissue growth factor may constitute a more specific target for future antifibrotic therapies.